ONO PHARMACEUTICAL CO., LTD. Logo

ONO PHARMACEUTICAL CO., LTD.

Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.

4528 | T

Overview

Corporate Details

ISIN(s):
JP3197600004
LEI:
Country:
Japan
Address:
大阪市中央区道修町二丁目1番5号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ONO PHARMACEUTICAL CO., LTD., established in 1717, is a research and development-oriented pharmaceutical company dedicated to discovering and delivering innovative medicines. With a legacy spanning over three centuries, the company focuses on addressing high unmet medical needs through the creation, manufacturing, and sale of prescription drugs. Its primary therapeutic areas include oncology, immunology, neurology, and other specialty fields, with a portfolio of treatments for conditions such as cancer and type II diabetes. The company is committed to a mission of fighting disease and pain by providing new therapeutic options to patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 01:00
Registration Form
確認書
Japanese 9.1 KB
2025-11-06 01:00
Interim Report
半期報告書-第78期(2025/04/01-2026/03/31)
Japanese 328.6 KB
2025-07-01 09:06
Registration Form
確認書
Japanese 9.2 KB
2025-07-01 09:00
Annual Report
訂正有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 1.3 MB
2025-06-20 02:00
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-06-19 09:06
Share Issue/Capital Change
臨時報告書
Japanese 39.9 KB
2025-06-19 09:05
Share Issue/Capital Change
臨時報告書
Japanese 41.7 KB
2025-06-19 09:02
Governance Information
内部統制報告書-第77期(2024/04/01-2025/03/31)
Japanese 26.0 KB
2025-06-19 09:01
Registration Form
確認書
Japanese 9.2 KB
2025-06-19 09:00
Annual Report
有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2024-11-06 01:00
Interim Report
半期報告書-第77期(2024/04/01-2025/03/31)
Japanese 334.0 KB
2024-11-06 01:00
Interim Report
確認書
Japanese 9.1 KB
2024-06-21 02:05
Post-Annual General Meeting Information
臨時報告書
Japanese 27.2 KB
2024-06-21 02:04
Governance Information
内部統制報告書-第76期(2023/04/01-2024/03/31)
Japanese 24.4 KB
2024-06-21 02:03
Registration Form
確認書
Japanese 9.2 KB

Automate Your Workflow. Get a real-time feed of all ONO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.